Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188666 | 0.89 | DDR1 (0.46) | DDR1DRD2DRD4DRD3RAB9A | |
| SCHEMBL5176971 | 0.89 | DDR1 (0.55) | DDR1RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5186813 | 0.86 | DDR1 (0.50) | DDR1DRD2DRD4DRD3EPHX2 | |
| SCHEMBL5901009 | 0.85 | DDR1 (0.44) | DDR1RAB9AALDH1A1EPHX2 | |
| SCHEMBL5178553 | 0.84 | DDR1 (0.51) | DDR1RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5177650 | 0.84 | HPGD (0.60) | DRD2DRD4DRD3RAB9AEPHX2 | |
| SCHEMBL5189566 | 0.83 | DDR1 (0.50) | DDR1RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5176431 | 0.83 | AKR1B1 (0.50) | DDR1RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5900698 | 0.83 | DDR1 (0.49) | DDR1RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5900712 | 0.82 | DDR1 (0.48) | DDR1RAB9AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116410-A1 | 4-Aminomethyl benzamidine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116410-A1 | 4-Aminomethyl benzamidine derivatives | F7, HABP2, F12 | DDR1 1764/4885DRD2 3657/4885DRD4 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.